Overview
Current NAV
10.4783
As on 30-Dec-2025
Fund Size
29.418 Cr
Managed by Swapnil P Mayekar
Expense Ratio
0.63%
Latest reported
Exit Load Rules
0
Conditions apply
Scheme Snapshot
This growth scheme operates in the equity small cap category with a risk profile of Very High Risk. Inception date 19-Nov-2024. Use the navigation above to explore performance, risk, portfolio holdings, analysis & exit load structure.
Data shown is for informational purposes only and may be delayed.
Returns
Green = Positive, Red = Negative| Period | Absolute % | CAGR % | Category % | Index % |
|---|---|---|---|---|
| 1D | -0.73 | — | — | — |
| 1W | -1.27 | — | — | — |
| 1M | -1.67 | — | — | — |
| 3M | 0.66 | — | 1.47 | — |
| 6M | 0.86 | — | 0.20 | — |
| 1Y | 0.08 | — | -2.14 | — |
| 3Y | — | — | 22.11 | — |
| 5Y | — | — | 14.61 | — |
| 10Y | — | — | — | — |
Top Holdings
Portfolio Allocation (Top 8+)
Company
Nature
Sector
% of Corpus
Lupin Ltd.
EQ
Healthcare
9.33
Fortis Healthcare Ltd.
EQ
Healthcare
8.87
Laurus Labs Ltd.
EQ
Healthcare
7.43
Aurobindo Pharma Ltd.
EQ
Healthcare
6.36
Alkem Laboratories Ltd.
EQ
Healthcare
5.94
Glenmark Pharmaceuticals Ltd.
EQ
Healthcare
5.43
Mankind Pharma Ltd.
EQ
Healthcare
4.72
Biocon Ltd.
EQ
Healthcare
4.44
Ipca Laboratories Ltd.
EQ
Healthcare
3.75
Krishna Institute of Medical Sciences Ltd
EQ
Healthcare
3.13
Abbott India Ltd.
EQ
Healthcare
2.90
Aster DM Healthcare Ltd.
EQ
Healthcare
2.79
Analysis Highlights
CONS
Higher expense ratio: 0.63%
PROS
1Y annualised returns higher than category average by 2.22%